Search
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigational[L45206] This therapy was developed by ADC Therapeutics and its accelerated approval for relapsed or refractory B-cell lymphoma is based on promising results from the LOTIS-2 clinical trial. … Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success.
Poliovirus type 2 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10796ApprovedInvestigationalThe vaccine contains purified and inactivated poliovirus type 2 that were grown from a continuous line of monkey kidney cells. … caused by poliovirus Type 2.
Mixtures: Polio Salk "Merieux" - Fertigspritze, Hexaxim Suspension for InjectionIdelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalFor the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other … More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K.
Vibrio cholerae CVD 103-HgR strain live antigen
go.drugbank.com/drugs/DB14443ApprovedInvestigational[A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801] … Serogroup O1 is responsible for the majority of cholera outbreaks.
L-Acetylleucine
go.drugbank.com/drugs/DB16956ApprovedInvestigationalDL-) form has been available in France since 1957 for the treatment of vertigo. … [A264439] Observational studies in patients with Niemann-Pick disease type C (NPC) suggested a beneficial symptomatic as well as neuroprotective disease-modifying effect of the DL-form of N-acetylleucine
Glimepiride
go.drugbank.com/drugs/DB00222ApprovedInvestigational[A177709] Glimepiride works by stimulating the secretion of insulin granules from pancreatic islet beta cells by blocking ATP-sensitive potassium channels (K<SUB>ATP</SUB> channels) and causing depolarization … [A177703] Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in 1995 for the treatment of T2DM.
Aminosalicylic acid
go.drugbank.com/drugs/DB00233ApprovedInvestigationalThe sodium salt of the drug is better tolerated than the free acid.
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisHydromorphone
go.drugbank.com/drugs/DB00327ApprovedIllicitInvestigational[A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795] … Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8.
Categories: Heterocyclic Compounds with 4 or More RingsElvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalElvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. … On September 24, 2014, the FDA approved the single pill form of elvitegravir.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseHuperzine A
go.drugbank.com/drugs/DB04864ApprovedInvestigationalWithdrawnIt is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease. … The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects.
Categories: Compounds used in a research, industrial, or household setting